Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers

Trial Profile

A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPR-206 (Primary)
  • Indications Acinetobacter infections; Gram-negative infections
  • Focus Pharmacokinetics
  • Acronyms BAL
  • Sponsors Spero Therapeutics

Most Recent Events

  • 13 Mar 2024 According to a Spero Therapeutics media release, results from this study were published in Antimicrobials and Chemotherapy in July 2023.
  • 19 Oct 2022 According to a Spero Therapeutics media release, data from this trial will be presented at the Infectious Disease Society of America (IDSA) IDWeek™ 2022.
  • 16 Feb 2022 Topline results presented in a Spero Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top